Abstract
The association between acute myeloid leukaemia (AML) and the aberrant expression of Hoxa9 is evidenced by (1) proviral activation of Hoxa9 and Meis1 in BXH-2 murine AML, (2) formation of the chimeric Nup98-HoxA9 transactivator protein as a consequence of the t(7;11) translocation in human AML, and (3) the strong expression of HoxA9 and Meis1 in human AML. In mouse models, enforced retroviral expression of Hoxa9 alone in marrow is not sufficient to cause rapid AML, while co-expression of Meis1 and Hoxa9 induces rapid AML. In contrast, retroviral expression of Nup98-HoxA9 is sufficient to cause rapid AML in the absence of enforced Meis1 expression. Previously, we demonstrated that Hoxa9 could block the differentiation of murine marrow progenitors cultured in granulocyte-macrophage colony-simulating factor (GM–CSF). These progenitors lacked Meis1 expression, could not proliferate in stem cell factor (SCF), but could differentiate into neutrophils when switched into granulocyte colony-simulating factor (G-CSF). Ectopic expression of Meis1 in these Hoxa9 cells suppressed their G-CSF-induced differentiation, permitted proliferation in SCF, and therein offered a potential explanation of cooperative function. Because Meis1 binds N-terminal Hoxa9 sequences that are replaced by Nup98, we hypothesized that Nup98-HoxA9 might consolidate the biochemical functions of both Hoxa9 and Meis1 on target gene promoters and might evoke their same lymphokine-responsive profile in immortalized progenitors. Here we report that Nup98-HoxA9, indeed mimicks Hoxa9 plus Meis1 coexpression – it immortalizes myeloid progenitors, prevents differentiation in response to GM–CSF, IL-3, G-CSF, and permits proliferation in SCF. Unexpectedly, however, Nup98-Hoxa9 also enforced strong transcription of the cellular Hoxa9, Hoxa7 and Meis1 genes at levels similar to those found in mouse AML's generated by proviral activation of Hoxa9 and Meis1. Using Hoxa9−/− marrow, we demonstrate that expression of Hoxa9 is not required for myeloid immortalization by Nup98-HoxA9. Rapid leukaemogenesis by Nup98-HoxA9 may therefore result from both the intrinsic functions of Nup98-HoxA9, as well as of those of coexpressed HOX and MEIS1 genes.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
- Nichelle C. Whitlock
- , Shana Y. Trostel
- …Adam G. Sowalsky
Oncogene Open Access 17 July 2020
-
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling
- Mara Salomé
- , Aoife Magee
- …Karen Keeshan
Cell Death & Disease Open Access 18 April 2018
-
MiR-139-5p is a potent tumor suppressor in adult acute myeloid leukemia
- K Krowiorz
- , J Ruschmann
- …F Kuchenbauer
Blood Cancer Journal Open Access 09 December 2016
Access options
Change institution
Buy or subscribe
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Learn more
Rent or buy this article
Get just this article for as long as you need it
$39.95
Learn more
Prices may be subject to local taxes which are calculated during checkout







References
Ahuja HG, Popplewell L, Tcheurekdjian L, Slovak ML . 2001 Gene Chrom. Cancer 30: 410–415
Borrow J, Shearman AM, Stanton VP, Becher R, Collins T, Williams AJ, Dube I, Katz F, Kwong YL, Morris C, Ohyashiki K, Toyama K, Rowley T, Housman DE . 1996 Nat. Genet. 12: 159–167
Calvo KR, Sykes DB, Pasillas M, Kamps MP . 2000 Mol. Cell. Biol. 20: 3274–3285
Calvo KR, Knoepfler PS, Sykes DB, Pasillas MP, Kamps MP . 2001 Proc. Natl. Acad. Sci. USA 98: 13120–13125
Chen J, Ruley HE . 1998 J. Biol. Chem. 273: 24670–24675
Ferretti E, Marshall H, Popperl H, Maconochie M, Krumlauf R, Blasi F . 2000 Development 127: 155–166
Fujino T, Suzuki A, Ito Y, Ohyashiki K, Hatano Y, Miura I, Nakamura T . 2002 Blood 99: 1428–1433
Golub TT, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, Bloomfield CD, Lander ES . 1999 Science 286: 531–537
Hatano Y, Miura I, Nakamura T, Yamazaki Y, Takahashi N, Miura AB . 1999 Br. J. Haematol. 107: 600–604
Kasper LH, Brindle PK, Schnabel CA, Pritchard CE, Cleary ML, van Deurse JM . 1999 Mol. Cell. Biol. 19: 764–776
Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE . 1999 Leukemia 13: 687–698
Kroon E, Krosl J, Thorsteindottir U, Baban S, Buchberg AM, Sauvageau G . 1998 EMBO J. 17: 3714–3725
Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G . 2001 EMBO J. 20: 350–361
Lawrence HJ, Rozenfeld S, Cruz C, Matsukuma K, Kwong A, Komuves L, Buchberg AM, Largman C . 1999 Leukemia 13: 1993–1999
Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, Largman C . 1997 Blood 89: 1922–1930
Moskow JJ, Bullrich F, Huebner K, Daar IO, Buchberg AM . 1995 Mol. Cell. Biol. 15: 5434–5443
Nakamura T, Largaespada DA, Shaughnessy JD, Jenkins NA, Copeland NG . 1996a Nat. Genet. 12: 149–153
Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen IM, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD . 1996b Nat. Genet. 12: 154–158
Nakamura T, Yamazaki Y, Hatano Y, Miura I . 1999 Blood 94: 741–747
Nishiyama M, Arai Y, Tsunematsu Y, Kobayashi H, Asami K, Yabe M, Kato S, Oda M, Eguchi H, Ohki M, Kaneko Y . 1999 Genes Chrom. Cancer 26: 215–220
Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD . 1998 Cancer Res. 58: 4269–4273
Rozovskaia T, Feinstein E, Mor O, Foa R, Blechman J, Nakamura T, Croce CM, Cimino G, Canaani E . 2001 Oncogene 20: 874–878
Schnabel CA, Jacobs Y, Cleary ML . 2000 Oncogene 19: 608–616
Shanmugam K, Green NC, Rambaldi I, Saragovi HU, Featherstone MS . 1999 Mol. Cell Biol. 19: 7577–7588
Shen WF, Montgomery JC, Rozenfeld S, Moskow JJ, Lawrence HF, Buchberg AM, Largman C . 1997 Mol. Cell. Biol. 17: 6448–6458
Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HF, Largman C . 1999 Mol. Cell. Biol. 19: 3051–3061
Swift GH, Liu Y, Rose SD, Bischof LJ, Steelman S, Buchberg AM, Wright CV, MacDonald RJ . 1998 Mol. Cell. Biol. 18: 5109–5120
Yamamoto K, Nakamura Y, Saito K, Furusawa S . 2000 Br. J. Haematol. 109: 423–426
Acknowledgements
MP Kamps is a scholar of the Leukemia Society of America. KR Calvo is supported by NIH Training Grant CA77109-01. DB Sykes is supported by a grant from the Department of Defense. Antisera against the mouse macrophage acetyl-LDL scavenger receptor was a kind gift from Dr Christopher Glass. We thank Dr Jeffrey Lawrence for the kind gift of Hoxa9−/− mice and Dr Mario Capecchi for permitting us to use this strain. We thank Dennis J Young in the UCSD Cancer Center's Flow Cytometry Shared Resource for his flow cytometry expertise and Dr James Feramisco for assistance in deconvolution microscopy. DNA sequencing was performed by the Molecular Pathology Shared Resource, UCSD Cancer Center, which is funded in part by NCI Cancer Center Support Grant #5P0CA23100-16. This work was supported by NIH grant CA56876.
Author information
Authors and Affiliations
Department of Pathology 9500 Gilman Drive, University of California School of Medicine, La Jolla, 92093-0612, California, CA, USA
Katherine R Calvo,David B Sykes,Martina P Pasillas&Mark P Kamps
Authors
- Katherine R Calvo
View author publications
You can also search for this author in PubMedGoogle Scholar
- David B Sykes
View author publications
You can also search for this author in PubMedGoogle Scholar
- Martina P Pasillas
View author publications
You can also search for this author in PubMedGoogle Scholar
- Mark P Kamps
View author publications
You can also search for this author in PubMedGoogle Scholar
Corresponding author
Correspondence to Mark P Kamps.
Rights and permissions
About this article
Cite this article
Calvo, K., Sykes, D., Pasillas, M. et al. Nup98-HoxA9 immortalizes myeloid progenitors, enforces expression of Hoxa9, Hoxa7 and Meis1, and alters cytokine-specific responses in a manner similar to that induced by retroviral co-expression of Hoxa9 and Meis1. Oncogene 21, 4247–4256 (2002). https://doi.org/10.1038/sj.onc.1205516
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205516
Keywords
- Hoxa9
- Nup98-HoxA9
- Meis1
- leukaemia
- AML
This article is cited by
-
Phase separation drives aberrant chromatin looping and cancer development
- Jeong Hyun Ahn
- Eric S. Davis
- Gang Greg Wang
Nature (2021)
-
Fusion proteins form onco-condensates
- Tanja Mittag
- Aseem Z. Ansari
Nature Structural & Molecular Biology (2021)
-
MEIS1 down-regulation by MYC mediates prostate cancer development through elevated HOXB13 expression and AR activity
- Nichelle C. Whitlock
- Shana Y. Trostel
- Adam G. Sowalsky
Oncogene (2020)
-
The genomics of acute myeloid leukemia in children
- Shannon E. Conneely
- Rachel E. Rau
Cancer and Metastasis Reviews (2020)
-
A Trib2-p38 axis controls myeloid leukaemia cell cycle and stress response signalling
- Mara Salomé
- Aoife Magee
- Karen Keeshan
Cell Death & Disease (2018)